Spyre Therapeutics climbs as investors reprice SPY001 UC data after $403M raise
Spyre Therapeutics shares rose as investors continued to digest April 13 Phase 2 SKYLINE topline results showing SPY001 delivered positive 12-week induction efficacy in moderate-to-severe ulcerative colitis. The move also follows the company’s recently completed $403 million upsized equity offering priced at $62 and subsequent closing.
1. What’s moving the stock today
Spyre Therapeutics (SYRE) is trading higher as the market continues to revalue the company after it reported positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial for SPY001 in moderate-to-severely active ulcerative colitis on April 13, 2026. The stock’s follow-through strength is also being supported by the company’s recently executed financing, which priced an upsized underwritten public offering at $62 per share and then closed in the days that followed, removing near-term balance-sheet uncertainty for many investors.
2. The catalyst investors are focusing on
The April 13 update is the key driver: Spyre said SPY001 produced positive initial induction topline results in the SKYLINE Part A dataset in ulcerative colitis, reinforcing the narrative that the program could be competitive in a crowded IBD market. With the stock now trading well above the offering price, today’s gain looks like incremental risk-on positioning tied to expectations for additional cohorts and future readouts from the company’s platform approach rather than a single new headline.
3. Financing overhang: from risk to runway
Spyre’s upsized equity deal (6.5 million shares at $62, about $403 million gross proceeds) and the subsequent closing have been a second, practical catalyst: it strengthened cash resources for upcoming clinical work while also establishing a widely referenced “deal price” for near-term trading. For momentum-oriented biotech investors, a cleaned-up funding picture can be as important as data itself, particularly heading into additional Phase 2 proof-of-concept milestones.
4. What to watch next
Traders are likely to stay keyed on the next steps in SKYLINE (including combination cohorts and any additional efficacy/safety detail that can sharpen comparisons vs established biologics), plus any further analyst target changes and volume spikes that confirm institutions are building positions rather than simply rotating after the offering. Any incremental trial updates, protocol expansions, or timing changes for upcoming readouts could quickly outweigh the day-to-day noise in a high-beta clinical-stage name.